QazCoVac-P -COVID-19 Subunit Vaccine / Research Institute for Biological Safety Problems - LARVOL DELTA

Pre-Clinical Safety and Immunogenicity Study of a Coronavirus Protein-Based Subunit Vaccine for COVID-19. (PubMed, Vaccines (Basel)) - "We used ELISA to measure antibody titers with the maximum mean geometric titer of antibodies in the animals' blood sera totaling approximately 8 log2. The results of this and other studies warrant recommending the QazCoVac-P vaccine for clinical trials."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

QAZCOVAC-P-I/II-01/2020: Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine (clinicaltrials.gov) - P1/2 | N=244 | Completed | Sponsor: Research Institute for Biological Safety Problems | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • CD4

Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine (clinicaltrials.gov) - P1/2; N=244; Active, not recruiting; Sponsor: Research Institute for Biological Safety Problems

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease